INT66819

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1996
Last Reported 2010
Negated 6
Speculated 0
Reported most in Abstract
Documents 41
Total Number 42
Disease Relevance 8.23
Pain Relevance 8.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2C9) oxidoreductase activity (CYP2C9) endoplasmic reticulum (CYP2C9)
Anatomy Link Frequency
liver 1
hair 1
bile 1
lung 1
saliva 1
CYP2C9 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 234 100.00 Very High Very High Very High
diclofenac 75 100.00 Very High Very High Very High
aspirin 57 100.00 Very High Very High Very High
Bile 2 98.00 Very High Very High Very High
pregabalin 78 97.68 Very High Very High Very High
fluoxetine 8 94.96 High High
nud 7 94.24 High High
Central nervous system 3 89.52 High High
Angina 5 89.28 High High
addiction 6 88.68 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 74 100.00 Very High Very High Very High
Hemorrhage 49 100.00 Very High Very High Very High
Toxicity 35 99.88 Very High Very High Very High
Adverse Drug Reaction 14 99.44 Very High Very High Very High
Colon Cancer 12 99.44 Very High Very High Very High
Disease 99 98.84 Very High Very High Very High
Adenoma 5 98.72 Very High Very High Very High
Lung Cancer 9 97.60 Very High Very High Very High
Injury 9 96.52 Very High Very High Very High
Nicotine Addiction 12 94.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism.
CYP2C9 Binding (Binding) of
1) Confidence 0.48 Published 2009 Journal Medicinal chemistry (Sh?riqah (United Arab Emirates)) Section Title Doc Link 19442216 Disease Relevance 0 Pain Relevance 0.07
By a series of docking studies and MD simulations, the binding pockets of CYP2C9 for the five drugs are explicitly defined that will be very useful for conducting mutagenesis studies, providing insights into the metabolic mechanism, which may be of relevance to the personalized drug.
CYP2C9 Binding (binding) of
2) Confidence 0.48 Published 2009 Journal Medicinal chemistry (Sh?riqah (United Arab Emirates)) Section Abstract Doc Link 19442216 Disease Relevance 0 Pain Relevance 0.09
Thus, a potential exists for in vivo interactions with other CYP2C9 substrates, including propofol.
CYP2C9 Binding (interactions) of
3) Confidence 0.48 Published 2002 Journal Anesthesiology Section Abstract Doc Link 11753007 Disease Relevance 0.09 Pain Relevance 0.09
More trials in this area are ongoing to test the concept that prospective genotyping of CYP2C9 and VKORC1 in treatment with warfarin and acenocoumarol improves the safety of the patients.
CYP2C9 Binding (genotyping) of
4) Confidence 0.45 Published 2008 Journal Eur J Clin Pharmacol Section Body Doc Link PMC2235910 Disease Relevance 0.16 Pain Relevance 0
Cytochrome P450 CYP2C9 metabolizes a wide variety of clinically important drugs, including phenytoin, tolbutamide, warfarin and a large number of non-steroidal anti-inflammatory drugs.
CYP2C9 Binding (metabolizes) of associated with inflammation and cinod
5) Confidence 0.37 Published 1996 Journal Pharmacogenetics Section Abstract Doc Link 8946475 Disease Relevance 0.09 Pain Relevance 0.09
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
CYP2C9 Binding (combination) of associated with cinod and hemorrhage
6) Confidence 0.37 Published 2009 Journal Expert Opin Drug Metab Toxicol Section Title Doc Link 19422321 Disease Relevance 0.23 Pain Relevance 0.36
It is postulated that CYP2C9 genotype is associated with NSAID-induced gastropathy.
CYP2C9 Binding (associated) of associated with cinod
7) Confidence 0.37 Published 2008 Journal J Dig Dis Section Abstract Doc Link 18419640 Disease Relevance 0.27 Pain Relevance 0.46
In addition, the observed intraethnic variability reinforces the need for proper selection of control subjects and points against the use of surrogate control groups for studies involving association of CYP2C8 or CYP2C9 alleles with adverse drug reactions or spontaneous diseases.
CYP2C9 Binding (association) of associated with adverse drug reaction and disease
8) Confidence 0.37 Published 2006 Journal Molecular diagnosis & therapy Section Abstract Doc Link 16646575 Disease Relevance 0.20 Pain Relevance 0
CONCLUSION: Both NSAID use and CYP2C9*2 and/ or *3 carriage are associated with a reduced risk of colorectal cancer.
CYP2C9 Binding (associated) of
9) Confidence 0.37 Published 2009 Journal Neth J Med Section Body Doc Link 19581657 Disease Relevance 0.07 Pain Relevance 0
Thus, it would appear that both CYP2D6 and CYP2C9 contribute to the formation of R-norfluoxetine, whereas only CYP2D6 is responsible for the conversion to S-norfluoxetine.
CYP2C9 Binding (contribute) of
10) Confidence 0.37 Published 2001 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11356927 Disease Relevance 0 Pain Relevance 0.33
For example, with the statement “the patient is a poor metabolizer of CYP2C9,” supporting knowledge must define the CYP2C9 genotype that would classify a patient as “a poor metabolizer of CYP2C9,” (e.g.
CYP2C9 Binding (metabolizer) of
11) Confidence 0.36 Published 2010 Journal BMC Bioinformatics Section Body Doc Link PMC2967740 Disease Relevance 0 Pain Relevance 0
For example, with the statement “the patient is a poor metabolizer of CYP2C9,” supporting knowledge must define the CYP2C9 genotype that would classify a patient as “a poor metabolizer of CYP2C9,” (e.g.
CYP2C9 Binding (metabolizer) of
12) Confidence 0.36 Published 2010 Journal BMC Bioinformatics Section Body Doc Link PMC2967740 Disease Relevance 0 Pain Relevance 0
Linkage disequilibrium between CYP2C9 and CYP2C8
CYP2C9 Binding (Linkage) of
13) Confidence 0.36 Published 2009 Journal Pharmacogenomics J Section Body Doc Link PMC2782405 Disease Relevance 0.18 Pain Relevance 0
This strong association implies that if any of the three relevant SNPs gives a positive result in a case–control study, it will be difficult to distinguish any association with CYP2C9 from an association with CYP2C8 and vice versa.
CYP2C9 Binding (association) of
14) Confidence 0.36 Published 2009 Journal Pharmacogenomics J Section Body Doc Link PMC2782405 Disease Relevance 0.09 Pain Relevance 0
Thus, an exploratory study in Europeans and/or Southwest Asians of association of the CYP2C9*144Cys allele with a trait (disease risk, therapy response and others) will usually be simultaneously studying CYP2C8 variation.
CYP2C9 Binding (association) of associated with disease
15) Confidence 0.36 Published 2009 Journal Pharmacogenomics J Section Body Doc Link PMC2782405 Disease Relevance 0.16 Pain Relevance 0
In a multivariate analysis, CYP2C9 359Leu remained associated with the non-ASP group (OR = 7.2 (2.6-20.3), P = 0.0002) even though 40% of these patients were under treatment with antiulcer drugs at the time of admission.
CYP2C9 Binding (associated) of
16) Confidence 0.36 Published 2010 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 20445534 Disease Relevance 0.22 Pain Relevance 0.83
Thus, DEX interacts with CYP2C9 both as inhibitor (K(i)=69.0 microM) and as substrate in vitro.
CYP2C9 Binding (interacts) of
17) Confidence 0.36 Published 2004 Journal Biopharm Drug Dispos Section Abstract Doc Link 15108219 Disease Relevance 0.13 Pain Relevance 0.20
Sequence analysis of the different PCR products revealed that other genes in the CYP2C locus were co-amplified in one of the methods applied, whereas the other two methods were specific for CYP2C9.
CYP2C9 Binding (specific) of
18) Confidence 0.35 Published 1999 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 9920790 Disease Relevance 0.08 Pain Relevance 0.08
A reduced risk of colorectal cancer was observed in individuals who used NSAIDs for more than a year (HR 0.45; 95% CI 0.28 to 0.71), and in carriers of an CYP2C9 variant allele associated with lower enzymatic activity (HR 0.67; 95% CI 0.47 to 0.96).
CYP2C9 Binding (associated) of
19) Confidence 0.35 Published 2009 Journal Neth J Med Section Body Doc Link 19581657 Disease Relevance 0.08 Pain Relevance 0
Although the impact of impaired enzyme activity in metabolism of carcinogens and procarcinogens has not been fully defined, an association of CYP2C9 variant alleles to DNA adduct levels in lung tissues as well as to lung cancer risk have been reported.
CYP2C9 variant Binding (association) of in lung associated with lung cancer
20) Confidence 0.35 Published 2001 Journal Acta Biochim. Pol. Section Abstract Doc Link 11833786 Disease Relevance 0.39 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox